Speed ​​up the development of effective drugs for new coronary pneumonia

At present, a new round of new crown pneumonia epidemic has emerged in some parts of the country
.

Since October 17, there have been many local outbreaks in the country, showing a rapid development trend, which has spread to 11 provinces within a week

After the outbreak of the new crown pneumonia epidemic, it quickly swept the world
.

The "global pandemic" of the epidemic has so far caused more than 200 million people to be diagnosed and killed more than 4 million people

However, the "cunning" level of the new coronavirus is far beyond imagination.
The constantly mutating strains such as the "Delta" virus are raging wildly in populous countries such as India.
The virus's toxicity and transmission power continue to increase.
This is the safety and effectiveness of the vaccine.
A test
.

Although experts and scholars in the field of biomedicine have tried various methods, humans’ current understanding of the new coronavirus is still limited

As early as the beginning of the outbreak, the "Remdesivir", which was used to treat the African Ebola virus, played an active role in preventing the worsening of severely ill patients
.

Judging from the results of the Phase III clinical trial of the drug, Redcivir reduces the possibility of patients developing to a more severe stage of the disease and speeds up the recovery of patients

Not long ago, according to media reports, the US pharmaceutical company Merck is developing a drug for the treatment of new crowns-Molnupiravir (Molnupiravir).
Trial data show that it not only can reduce the probability of hospitalization or death by 50%, but also The mutant strains are also effective and easy to use.
They are only taken orally without intravenous injection
.

According to the company, it is currently planning to submit an emergency use authorization application to the U.

Chinese pharmaceutical companies are also accelerating the development of effective drugs
.

In September of this year, the intravenous COVID-19 human immunoglobulin (pH4) developed by Tiantan Biological, a subsidiary of Sinopharm Group China, obtained the "Clinical Trial Approval for Drugs" issued by the National Medical Products Administration, and was approved to carry out clinical trials.

In addition, there are many drugs around the world that are in phase III clinical trials.
If the research and development progresses smoothly, it is expected that new crown treatment drugs will be launched from the end of this year to next year
.

Whether it is Remdesivir, Monabilavir, or specific immunoglobulins, neutralizing antibodies, human progress and exploration in the field of biomedical technology are the confidence and support for us to compete with viruses